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From blood to lung tissue: effect of
cigarette smoke on DNA methylation and
lung function
Maaike de Vries1,2* , Diana A van der Plaat1,2, Ivana Nedeljkovic3, Rikst Nynke Verkaik-Schakel4, Wierd Kooistra2,5,
Najaf Amin3, Cornelia M van Duijn3, Corry-Anke Brandsma2,5, Cleo C van Diemen6, Judith M Vonk1,2
and H Marike Boezen1,2
Abstract
Background: Genetic and environmental factors play a role in the development of COPD. The epigenome, and
more specifically DNA methylation, is recognized as important link between these factors. We postulate that DNA
methylation is one of the routes by which cigarette smoke influences the development of COPD. In this study, we
aim to identify CpG-sites that are associated with cigarette smoke exposure and lung function levels in whole
blood and validate these CpG-sites in lung tissue.
Methods: The association between pack years and DNA methylation was studied genome-wide in 658 current
smokers with >5 pack years using robust linear regression analysis. Using mediation analysis, we subsequently
selected the CpG-sites that were also associated with lung function levels. Significant CpG-sites were validated in
lung tissue with pyrosequencing and expression quantitative trait methylation (eQTM) analysis was performed to
investigate the association between DNA methylation and gene expression.
Results: 15 CpG-sites were significantly associated with pack years and 10 of these were additionally associated
with lung function levels. We validated 5 CpG-sites in lung tissue and found several associations between DNA
methylation and gene expression.
Conclusion: This study is the first to validate a panel of CpG-sites that are associated with cigarette smoking and
lung function levels in whole blood in the tissue of interest: lung tissue.
Keywords: Cigarette smoking, Lung function, DNA methylation, EWAS, Lung tissue
Background
Chronic Obstructive Pulmonary Disease (COPD) is a
chronic and progressive inflammatory lung disease with
cigarette smoking as the main risk factor. COPD is charac-
terized by persistent airflow limitation and COPD patients
suffer from severe respiratory symptoms, overall resulting in
a poor quality of life [1]. The global prevalence of COPD is
10.7% [2], resulting in a high economic and societal burden.
In 2015, 5% of all deaths globally were caused by COPD and
it is expected that COPD will be the third leading cause of
death worldwide in 2030 (WHO 2016).
The development of COPD is known to be associated
with both genetic [3–5] and environmental factors [6]
and their interactions [7]. However, the genome-wide as-
sociation studies (GWAS) and genome-wide interaction
studies (GWIS) that have been performed so far identified
variants in COPD susceptibility genes that only explain a
very small part of the variation in the onset of COPD [8].
As a consequence, the epigenome is increasingly recog-
nized as an important link between changes to the inherited
genome and environmental exposures such as cigarette
smoke [9]. The epigenome comprises several epigenetic
mechanisms that affect gene expression without modifying
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the DNA sequence. These epigenetic mechanisms are
highly dynamic and changes can be induced by environ-
ment exposures, diseases and ageing [10].
One well-defined epigenetic mechanism is DNA
methylation, which is tissue-specific and involves the
binding of a methyl group to a cytosine base adjacent to
a guanine base, a so called CpG-site. CpG rich sites are
found in the regulatory regions of the DNA and methy-
lation of CpG-sites in these regulatory regions leads to a
decrease in gene expression [11]. It has been shown that
DNA methylation is highly affected by environmental
exposures such as air pollution and cigarette smoke
[12–14]. Next to the fact that exposure to cigarette
smoke is an important risk factor for COPD, it is also
strongly associated with lower lung function levels
[15, 16]. Hence, we postulate that DNA methylation plays
an important role in the etiology of COPD by mediating
the effect that cigarette smoking has on lung function
levels. In this study, we aim to identify these CpG-sites by
performing an epigenome-wide association study (EWAS)
in whole blood in current smokers and validate these




As indicated in the flowchart in Fig. 1, our complete
study can be divided into two consecutive studies.
Study I: Epigenome-wide association study (EWAS) in whole
blood
We performed an epigenome-wide association study
(EWAS) in whole blood to identify differential DNA
methylation related to pack years in a selection of
current smokers from the LifeLines population-based
cohort study. Subsequently, we studied whether the
identified CpG-sites were also associated with lung func-
tion levels using mediation analysis.
Study II: Validation study in lung tissue
We validated the significant mediating CpG-sites in actual
lung tissue. Subsequently, we studied the association be-
tween these CpG-sites and gene expression in lung tissue.
A detailed description of the study population and
measurements can be found in the online supplement
(Additional file 1).
Study I: Epigenome-wide association study (EWAS) in
whole blood
Study population
The association between pack years as a cumulative
measurement of cigarette smoking and DNA methyla-
tion in whole blood was studied in 658 subjects from
the Dutch general population-based cohort study Life-
Lines at baseline [17]. All selected subjects were
current smokers with a smoking history of at least 5
pack years.
Fig. 1 Flowchart of the study
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Measurements
DNA methylation levels in whole blood were determined
with the Illumina Infinium Human Methylation 450 K
array. After quality control, the final dataset contained
DNA methylation data presented as beta values for 420,938
CpG probes [18] (See supplementary methods for sample
processing and quality control).
Statistical analyses
Epigenome-wide association analysis (EWAS) in
whole blood We assessed the association between pack
years in current smokers and epigenome-wide DNA
methylation in whole blood. We performed robust linear
regression using the MASS package in R and adjusted
the model for the potential confounders age and gender.
To adjust for technical variation, principal components
were calculated using the 220 control probes incorpo-
rated in the Illumina 450 K chip. The principal compo-
nents that explain >1% of the technical variation (N = 7)
were included in the analysis. To adjust for the cellular
heterogeneity of the whole blood samples, we included
proportional white blood cell counts of mononuclear
cells, lymphocytes, neutrophils and eosinophils obtained
by standard laboratory techniques.
Mediation analysis To assess if the CpG-sites identified in
the EWA study were also associated with lung function
levels, we performed mediation analysis using the R-package
Mediation [19]. For every individual CpG-site, the Average
Causal Mediation Effect (ACME), Average Direct Effect
(ADE), Total Effect and Proportion Mediated was calculated.
When the p-value of ACME was below 0.05 for a particular
CpG-site (tested 2-sided), this CpG-site was considered to
be significantly associated with lung function levels.
Study II: Validation study in lung tissue
Study population
DNA methylation in lung tissue was studied in patients
undergoing lung resection, lung volume reduction or trans-
plant surgery in the University Medical Center Groningen as
previously described [20]. If resection surgery was conducted
for tumor removal, macroscopically normal lung tissue was
taken far distant form the tumor. All samples were histologi-
cally checked for abnormalities using standard haematoxylin
and eosin staining. To reach a power of 90% with an alpha of
5%, we selected a total of 47 subjects, being 16 never
smokers, 15 ex-smokers and 16 current smokers. The power
analysis can be found in the online supplement. All ex- and
current smokers had a smoking history of >5 pack years and
all ex-smokers quitted smoking for at least 1 year.
We studied gene expression in 36 of the 47 selected
subjects included in our lung tissue validation study [20].
Measurements
DNA methylation in lung tissue DNA methylation in
lung tissue was determined with the PyroMark Q48 Autop-
rep System. Quality of the pyrosequencing was assessed for
every CpG-site in all the subjects individually and the subject
was excluded for a particular CpG-site if the default software
quality control was not passed. Primers for cg01940273 did
not match with the original sequence and cg01940273 was
excluded from the validation study. Primer sequences are
shown in the online supplement.
Gene expression in lung tissue Total RNA was ex-
tracted from lung tissue at Rosetta Inpharmatics Gene Ex-
pression Laboratory (Seattle, WA, USA). mRNA profiling
was performed using a custom-made Affymetrix HU133
array (GPL 10379) containing 751 controls probe sets and
51,627 non-control probe sets. Gene expression was nor-
malized with the Robust Multichip Average method im-
plemented in the Affymetrix Power Tools software [20].
Statistical analysis
DNA methylation in lung tissue The association be-
tween smoking status and DNA methylation in lung tis-
sue was studied using linear regression analysis using R.
The analyses were adjusted for the potential confounders
age and gender.
Expression quantitative trait methylation (eQTM)
analysis in lung tissue For the CpG-sites that were dif-
ferentially methylated in lung tissue, we tested the associ-
ation between DNA methylation levels and gene
expression, i.e. expression quantitative trait methylation
(eQTM) analysis. Per CpG-site, all the gene expression
probe sets within 1 MB on either side were selected. An
association was considered significant when the p-value
was lower than the Bonferroni adjusted p-value (=0.05 /
the number of probe sets within a 2 MB window of the in-
dicated CpG-site).
Results
Study I: Epigenome-wide association study (EWAS) in
whole blood
Study population
Population characteristics are shown in Table 1. Notably,
the study population was non-random, i.e. selected
based on the presence or absence of airway obstruction.
Epigenome-wide association analysis (EWAS) in whole blood
The EWAS in whole blood identified 15 CpG-sites that were
significantly (Bonferroni corrected p-value < 0.05/420938 =
1.19 × 10^− 7) associated with pack years (Fig. 2). Higher
number of pack years was associated with lower levels of
DNA methylation in 13 of the 15 identified CpG-sites (see
Table 2). We identified two novel CpG-sites, cg22994830
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annotated to Protein Kinase CAMP-Dependent Type 1
Regulatory Subunit Beta (PRKAR1B) and cg20451986 lo-
cated in the intergenic region of 11q25 between the genes
loc100126239 and Junctional Adhesion Molecule 3 (JAM3).
As indicated in Table 2, we identified several CpG-sites to
be related to pack years, that were described in earlier stud-
ies in association with smoking status [12, 21–24]. An over-
view of all significant CpG sites at nominal p-value < 0.05
can be obtained upon request by the corresponding author.
Mediation analysis
The mediation analysis revealed that 10 CpG-sites were
significantly associated with lung function levels
(Additional file 2).
Study II: Validation study in lung tissue
Study population
We validated DNA methylation levels in lung tissue of 47
subjects, divided into 3 equal groups based on smoking
status (see Additional file 3 for subject characteristics).
DNA methylation in lung tissue
Figure 3 shows that the current smokers had significant
lower DNA methylation levels at 4 out of the 9 CpG
sites than never smokers (Bonferroni corrected p-value
of 0.05/9=0.00556). For cg21566642, the DNA methyla-
tion levels were significantly different between current
and never smokers at a nominal p-value of 0.05. An
overview of the complete analysis can be found in the
online supplement (Additional file 4).
Expression quantitative trait methylation (eQTM) analysis in
lung tissue
DNA methylation at cg05575921 and cg21161138 (the
two CpG-sites annotated to AHRR) was significantly
associated with gene expression levels of AHRR in lung
tissue (Fig. 4a and c). As indicated in Fig. 4b and d,
current smokers showed lower DNA methylation levels
together with higher expression levels compared to ex-
and never smokers. For the other 3 differentially methyl-
ated CpG-sites in lung tissue, we found novel significant
associations with gene expression levels. DNA methyla-
tion levels at cg05951221 and cg21566642, located in the
intergenic region on chromosome 2, were associated
with gene expression levels of the genes Autophagy Re-
lated 16 Like1 (ATG16L1) and DIS3 Like 3′-5′Exoribonu-
clease (DIS3L2) (Fig. 5a-d). DNA methylation levels at
cg06126421, located in the intergenic region on chromo-
some 6, were associated with gene expression levels of the
genes Mucin 21 (MUC21) and Tubulin Beta Class I
(TUBB) (Fig. 5e-f). A complete overview of the eQTM
analysis can be found in Additional file 5.
Discussion
In this study, we showed that DNA methylation at 15
CpG-sites was significantly associated with pack years.
Next to previously described CpG-sites, we identified 2
novel CpG-sites: cg22994830, annotated to PRKAR1B,
Table 1 Population characteristics
LifeLines Cohort
Number 658
Males, N (%) 375 (57,0)
Age, years (range) 46 (22–79)
Pack year, years, mean (range) 20,6 (5–100)
FEV1/FVC (%), mean (range) 71,7 (40,1 – 92,4)
FEV1(%pred)*, mean (range) 94,4 (47,7 – 138,4)
COPD cases, N (%) 279 (42,4)
GOLD COPD Stage ≥ 2†, N (%) 102 (15,6)
* Calculated with GLI-2012 if possible
† COPD GOLD stage > 2 (FEV1/FVC < 70% and FEV1 between 50 and 80%
of predicted)
COPD, Chronic Obstructive Pulmonary Disease; FEV1, Forced Expiratory Volume
in 1 s; FVC, Forced Vital Capacity
Fig. 2 Manhattan plot of the EWAS on pack years in current smokers. Every dot represents an individual CpG-site. Location on the X-axis indicates
the chromosomal position and location on the Y-axis indicates the inversed log [10] p-value. Horizontal line indicates genome wide significance
(p < 1.19 × 10^− 7)
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Table 2 Genome-wide significant results of EWAS in whole blood
CpG-site B SE P-value Adj. P-value Gene annotation Gene function#
cg05575921* − 0.00360 0.00043 6.80E-17 2.86E-11 AHRR Repressor of AHR, important in dioxin toxicity and involved
in regulation of cell growth and differentiation
cg21566642* − 0.00176 0.00024 1.21E-13 5.09E-08 NA NA
cg03636183* − 0.00211 0.00029 1.55E-13 6.53E-08 F2RL3 Plays a role in platelet activation and hypomethylation may
be associated with human lung cancer
cg05951221* − 0.00130 0.00018 2.01E-13 8.48E-08 NA NA
cg01940273* − 0.00143 0.00020 4.20E-13 1.77E-07 NA NA
cg06126421* − 0.00230 0.00033 2.75E-12 1.16E-06 NA NA
cg15342087* − 0.00092 0.00014 1.23E-11 5.19E-06 NA NA
cg24859433* − 0.00089 0.00014 3.91E-11 1.65E-05 NA NA
cg27241845* − 0.00110 0.00018 2.21E-09 9.30E-04 NA NA
cg20451986 0.00104 0.00018 4.85E-09 2.04E-03 NA NA
cg12876356* − 0.00244 0.00042 7.55E-09 3.18E-03 GFI1 Transcription repressor essential for hematopoiesis
cg09935388* − 0.00218 0.00040 5.42E-08 2.28E-02 GFI1 Transcription repressor essential for hematopoiesis
cg21161138* − 0.00106 0.00020 7.10E-08 2.99E-02 AHRR Repressor of AHR, important in dioxin toxicity and involved
in regulation of cell growth and differentiation
cg22994830 0.00102 0.00019 7.17E-08 3.02E-02 PRKAR1B Involved in cAMP signaling in cells
cg18146737* − 0.00256 0.00048 8.19E-08 3.45E-02 GFI1 Transcription repressor essential for hematopoiesis
*Associated with smoking status in previous studies
#Gene function obtained by www.genecards.org
Fig. 3 DNA methylation levels in lung tissue. CpG-sites that differ in DNA methylation levels between never smokers (blue circles), ex-smokers (gray
squares) and current smokers (yellow triangles) are shown
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and cg20451986, located in the intergenic region of
chromosome 11. 10 CpG-sites were additionally associ-
ated with lung function levels and we validated 5 of these
CpG-sites in lung tissue. We found several significant as-
sociations between DNA methylation and gene expression
in lung tissue. Moreover, we found novel associations
for the CpG-sites located in the intergenic regions of
chromosome 2 and 6 and biological plausible genes in
lung tissue.
In our EWA study, we identified 2 novel CpG-sites as-
sociated with pack years. One of them, cg22994830, is
located in the body of PRKAR1B. As a regulatory sub-
unit of cyclic AMP-dependent protein kinase A, this
gene is involved in several cellular events including ion
transport, metabolism and transcription. PRKAR1B has
shown to be implicated in neurodegenerative disorders,
however, a role for PRKAR1B in pulmonary diseases is
currently unknown [25]. The other novel CpG-site
cg20451986 has not been annotated to a gene yet. The
gene that is closest to this CpG-site, at approximately
10,000 base pairs, is JAM3, a gene involved in cell-cell
adhesion. While we performed an EWA study on the as-
sociation between DNA methylation and pack years as a
cumulative measurement of exposure to cigarette smoke,
as reviewed by Gao et al, earlier studies investigated dif-
ferences in DNA methylation levels between never and
current smokers [22]. Nevertheless, we identified several
CpG-sites that have been described before. Our third
most significant CpG-site cg03636183 located in the
gene F2RL3, was one of the first sites that was found to
be associated with smoking status [23]. In addition, a
study by Zeilinger et al showed associations of CpG-sites
located in the genes AHRR, GFI1, F2RL3 and the un-
known intergenic regions at chromosome 2 and 6 with
smoking status [12]. Nine of our identified CpG-sites were
identical to the CpG-sites discovered by Zeilinger’s study.
A major strength of our study is that we validated our
findings in lung tissue, the actual tissue of interest. This
is in contrast to previous studies in which the most sig-
nificant CpG-sites from the EWAS were validated by
replication in whole blood of other populations [12, 13,
23]. In our study, DNA methylation at one of the
CpG-sites located in the body of AHRR, cg21161138,
was significantly lower in current smokers compared to
never smokers in lung tissue, in line with previous find-
ings by Shenker et al [24]. In addition, the association
Fig. 4 Association between DNA methylation levels and gene expression of AHRR in lung tissue. a and c) DNA methylation levels are presented on
the X-axis and the normalized gene expression levels are shown on the Y-axis. Blue circles = never smokers, gray squares = ex-smokers and
yellow triangles = current smoker. b and d) DNA methylation levels are presented on the X-axis and the average of the normalized gene
expression levels distributed per 2% DNA methylation are shown on the Y-axis. The upper part with yellow bars represents current smokers, the
middle part with gray bars represents ex-smokers and the lower part with blue bars represent never smokers
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between DNA methylation of cg21161138 and lower
gene expression of AHRR in lung tissue also confirms
findings of that earlier study. However, we were able to
validate 4 additional CpG-sites in lung tissue. The fact
that we could confirm a total of 5 CpG-sites, identified
in whole blood, in lung tissue suggests that changes in
DNA methylation in response to cigarette smoking dir-
ectly occur at the local level in the lung. For cg03636183
located in the body of F2RL3, we neither found differ-
ences upon smoking in lung tissue nor an association
between DNA methylation levels and gene expression.
Since the intensities of the nucleotide peaks in the pyro-
sequence run of cg03636183 were low compared to
other assays, despite the use of several different primers
sets, we cannot exclude that actual differences in DNA
methylation in lung tissue are masked by technical
issues.
Several cross-sectional studies strongly suggest that
DNA methylation in whole blood can be partially normal-
ized upon smoking cessation [21, 26, 27]. In our study, we
found that DNA methylation levels of ex-smokers are be-
tween the levels of never and current smokers for the 5
CpG-sites that are differentially methylated upon smoking.
Moreover, with the eQTM analysis, we showed that for
AHRR both DNA methylation and gene expression levels
of ex-smokers tends more towards the levels observed for
never smokers compared to current smokers. Even though
this is cross-sectional data, it implies a reversible character
of DNA methylation.
After identification and validation of CpG-sites that
are associated with exposure to cigarette smoke in lung
tissue, an important next step is to assess the functional
relevance of the CpG-sites. For AHRR, the function is
well studied. Briefly, AHRR inhibits the aryl hydrocarbon
receptor pathway, which is involved in the removal of
harmful environmental chemicals, including cigarette
smoke. Cigarette smoking results in decreased DNA
methylation and this decreased DNA methylation subse-
quently increases the expression of AHRR. This leads to
reduced removal of harmful compounds and thereby
thus potentially increasing the damage caused by these
compounds [28]. In contrast, the other 3 CpG-sites that
are different with smoking status in lung tissue have not
yet been annotated to a gene, making it impossible to as-
sess the potential function of DNA methylation at these
sites. By performing an eQTM analysis, we tried to iden-
tify the genes that are regulated by these CpG-sites. For
the 2 CpG-sites at chromosome 2, we found associations
Fig. 5 eQTM analysis for CpG-sites at the intergenic regions on chromosome 2 and 6. DNA methylation levels are presented on the X-axis en the normalized
gene expression levels are shown on the Y-axis. Blue circles = never smokers, gray squares = ex-smokers and yellow triangles = current smokers
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with gene expression of ATG16L1 and DIS3L2. ATG16L1
is an essential component of the autophagy pathway and
mutations in this gene have been associated with in-
flammatory bowel disease. Since proper function of
ATG16L1 is necessary for host-defense responses against
micro-organisms and inflammatory responses in Crohn’s
disease, this gene might be relevant in the respiratory
system as well [29]. DIS3L2 belongs to the family of
exo-ribonucleases, key enzymes involved in the control
of messenger RNA stability. DIS3L2 has been associated
with human diseases such as Perlman syndrome and
Wilm’s tumor, but a role in pulmonary diseases has not
been described [30]. For cg06126421 located at the inter-
genic region of chromosome 6, we found an association
between DNA methylation levels and the expression of
the genes TUBB and MUC21. TUBB encodes a beta tubu-
lin protein of the microtubule cytoskeleton and has shown
to be involved in microcephaly with structural brain ab-
normalities in humans. A role for TUBB in lung-related
pathologies, however, is currently unknown [31]. MUC21
belongs to group of 22 mucin proteins, the major glyco-
protein components of mucus, which forms the protective
layer of the epithelial surface. Since overproduction of mu-
cins is associated with common respiratory diseases in-
cluding COPD, asthma and cystic fibrosis [32], MUC21 is
a biological plausible gene and further investigations into
the inverse association between DNA methylation at
cg06126421 and the expression ofMUC21 are warranted.
While our study is one of the first studies to validate a
large panel of CpG-sites in actual lung tissue, we have to
consider some limitations of our study. First, the results of
the mediation analysis should be interpreted with caution.
In our study, we used mediation analysis to select
CpG-sites that were associated with lung function levels
rather than implying biological mediation. We used pack
years as cumulative measurement of the exposure to
cigarette smoke to assess the association between cigarette
smoking and DNA methylation. However, the number
of pack years is estimated from self-reported informa-
tion obtained from questionnaires of the LifeLines
population-based cohort study. It has been suggested that
self-reported estimations of smoking may underestimate
the true smoking prevalence, since cigarette smoking is
often interpreted as socially undesirable behavior [33].
Moreover, it has been stated that DNA methylation levels
at specific CpG-sites in the genes AHRR and F2RL3 are a
better estimate for the exposure to cigarette smoke than
pack years derived from self-report [34]. Within the medi-
ation analysis, this potential misclassification of exposure
to cigarette smoke may lead to overestimation of the me-
diation effect [35]. Furthermore, with the cross-sectional
design of our study, we cannot infer causality from the
mediation analysis. A second potential limitation of our
study is that most of the lung tissue was obtained from
tumor resection surgery. Although all the tissue has been
histologically checked for abnormalities, DNA methyla-
tion might be affected by the tumor and potential metas-
tases. However, since this holds for all groups under study,
we assume that it will not lead to differences in DNA
methylation between the groups.
Conclusions
We identified 15 CpG-sites that were associated with
pack years, of which 2 CpG-sites were novel. From the
10 CpG-sites that were also associated with lung func-
tion levels, 5 CpG-sites could be validated in lung tissue.
Significant associations with expression levels of bio-
logical plausible genes suggest a functional role for DNA
methylation in lung tissue. Overall, our study showed for
the first time that a panel of CpG-sites associated with
cigarette smoking and lung function levels identified in
whole blood is also associated with exposure to cigarette
smoke in the tissue of interest, i.e. the lung. Further
research should reveal the functional relevance of
these CpG-sites in the lung and their role in the etiology
of COPD.
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